Indivior Pharmaceuticals, Inc. INDV Debt-to-equity

Debt-to-equity at other companies

AlkermesALKS

0.9×+0.9×

JAN

Janus Living JAN

0×-0.5×

Revenue$317.0M+19.2%

Gross profit$277.0M+24.8%

Operating income$137.0M+108%

Net income$89.0M+89.4%

EPS (diluted)$0.69+81.6%

Cash & equivalents$175.0M-53.0%

Total debt$509.0M+37.6%

Total equity-$144.0M+49.5%

Total assets$1.2B-12.9%

Operating cash flow-$9.0M-112%

CapEx$20.0M+300%

Free cash flow-$29.0M-141%

Market cap$4.53B+213%

Enterprise value$4.86B+242%

P/E18×—

P/S3.5×+2.3×

Gross margin81.3%+1.5pp

Operating margin25.8%+23.3pp

Net margin19.4%+18.9pp

FCF margin-14.9%—

Return on equity-117%—

Current ratio0.9×0.0×